TF and chronic myelogenous leukemia, BCR-ABL1 positive: To investigate the targeting ability of Ab@Tf-Cou6-PLGA NPs in vivo, transferrin-modified Ab@Tf-Cou6-PLGA NPs and unmodified Ab@Cou6-PLGA NPs were injected into CML model mice at a dose of 2 mg through the tail vein.